Reference
1. Sundström Rehal M, Tjäder I, Wernerman J. Nutritional needs for the
critically ill in relation to inflammation. Current opinion in clinical
nutrition and metabolic care. 2016;19(2):138-43.
2. McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR,
Braunschweig C, et al. Guidelines for the Provision and Assessment of
Nutrition Support Therapy in the Adult Critically Ill Patient: Society
of Critical Care Medicine (SCCM) and American Society for Parenteral and
Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr.
2016;40(2):159-211.
3. Powers J, Samaan K. Malnutrition in the ICU patient population.
Critical Care Nursing Clinics. 2014;26(2):227-42.
4. Koekkoek KW, van Zanten AR. Nutrition in the critically ill patient.
Current Opinion in Anesthesiology. 2017;30(2):178-85.
5. McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR,
Braunschweig C, et al. Guidelines for the provision and assessment of
nutrition support therapy in the adult critically ill patient: Society
of Critical Care Medicine (SCCM) and American Society for Parenteral and
Enteral Nutrition (ASPEN). Journal of Parenteral and Enteral Nutrition.
2016;40(2):159-211.
6. Adeva‐Andany MM, Calvo‐Castro I, Fernández‐Fernández C,
Donapetry‐García C, Pedre‐Piñeiro AM. Significance of l‐carnitine for
human health. IUBMB life. 2017;69(8):578-94.
7. Pekala J, Patkowska-Sokola B, Bodkowski R, Jamroz D, Nowakowski P,
Lochynski S, et al. L-carnitine–metabolic functions and meaning in
humans life. Curr Drug Metab. 2011;12(7):667-78.
8. Uziel G, Garavaglia B, Di Donato S. Carnitine stimulation of pyruvate
dehydrogenase complex (PDHC) in isolated human skeletal muscle
mitochondria. Muscle Nerve. 1988;11(7):720-4.
9. Amat di San Filippo C, Taylor MR, Mestroni L, Botto LD, Longo N.
Cardiomyopathy and carnitine deficiency. Mol Genet Metab.
2008;94(2):162-6.
10. Oami T, Oshima T, Hattori N, Teratani A, Honda S, Yoshida T, et al.
l-carnitine in critically ill patients—a case series study. Renal
Replacement Therapy. 2018;4(1):13.
11. Duranay M, Akay H, Yilmaz FM, Senes M, Tekeli N, Yucel D. Effects of
L-carnitine infusions on inflammatory and nutritional markers in
haemodialysis patients. Nephrol Dial Transplant. 2006;21(11):3211-4.
12. Dastan F, Talasaz AH, Mojtahedzadeh M, Karimi A, Salehiomran A, Bina
P, et al. Randomized Trial of Carnitine for the Prevention of
Perioperative Atrial Fibrillation. Semin Thorac Cardiovasc Surg.
2018;30(1):7-13.
13. Lee B-J, Lin J-S, Lin Y-C, Lin P-T. Antiinflammatory effects of
L-carnitine supplementation (1000 mg/d) in coronary artery disease
patients. Nutrition. 2015;31(3):475-9.
14. Lysiak W, Lilly K, DiLisa F, Toth P, Bieber L. Quantitation of the
effect of L-carnitine on the levels of acid-soluble short-chain acyl-CoA
and CoASH in rat heart and liver mitochondria. Journal of Biological
Chemistry. 1988;263(3):1151-6.
15. Broderick TL, Quinney HA, Lopaschuk GD. Carnitine stimulation of
glucose oxidation in the fatty acid perfused isolated working rat heart.
Journal of Biological Chemistry. 1992;267(6):3758-63.
16. Gülcin İ. Antioxidant and antiradical activities of L-carnitine.
Life sciences. 2006;78(8):803-11.
17. Binienda ZK, Ali SF. Neuroprotective role of L-carnitine in the
3-nitropropionic acid induced neurotoxicity. Toxicology letters.
2001;125(1-3):67-73.
18. Augustyniak A, Skrzydlewska E. The influence of L-carnitine
suplementation on the antioxidative abilities of serum and the central
nervous system of ethanol-induced rats. Metabolic brain disease.
2010;25(4):381-9.
19. Miguel-Carrasco JL, Monserrat MT, Mate A, Vázquez CM. Comparative
effects of captopril and l-carnitine on blood pressure and antioxidant
enzyme gene expression in the heart of spontaneously hypertensive rats.
European journal of pharmacology. 2010;632(1-3):65-72.
20. Setia S, Sanyal SN. Nuclear Factor Kappa B: A Pro-Inflammatory,
Transcription Factor− Mediated Signalling Pathway in Lung Carcinogenesis
and Its Inhibition By Nonsteroidal Anti-Inflammatory Drugs. Journal of
Environmental Pathology, Toxicology and Oncology. 2012;31(1).
21. Siomek A. NF-κB signaling pathway and free radical impact. Acta
Biochimica Polonica. 2012;59(3).
22. Zambrano S, Blanca AJ, Ruiz-Armenta MV, Miguel-Carrasco JL, Arévalo
M, Vázquez MJ, et al. L-Carnitine protects against arterial
hypertension-related cardiac fibrosis through modulation of PPAR-γ
expression. Biochemical Pharmacology. 2013;85(7):937-44.
23. Shakeri A, Tabibi H, Hedayati M. Effects of l‐carnitine supplement
on serum inflammatory cytokines, C‐reactive protein, lipoprotein (a),
and oxidative stress in hemodialysis patients with Lp (a)
hyperlipoproteinemia. Hemodialysis international. 2010;14(4):498-504.
24. Savica V, Santoro D, Mazzaglia G, Ciolino F, Monardo P, Calvani M,
et al. L-carnitine infusions may suppress serum C-reactive protein and
improve nutritional status in maintenance hemodialysis patients. J Ren
Nutr. 2005;15(2):225-30.
25. Volek JS, Judelson DA, Silvestre R, Yamamoto LM, Spiering BA,
Hatfield DL, et al. Effects of carnitine supplementation on
flow-mediated dilation and vascular inflammatory responses to a high-fat
meal in healthy young adults. Am J Cardiol. 2008;102(10):1413-7.
26. Rafraf M, Karimi M, Jafari A. Effect of L-carnitine supplementation
in comparison with moderate aerobic training on serum inflammatory
parameters in healthy obese women. J Sports Med Phys Fitness.
2015;55(11):1363-70.
27. Sahebkar A. Effect of L-carnitine supplementation on circulating
C-reactive protein levels: A systematic review and meta-analysis.
Journal of medical biochemistry. 2015;34(2):151.
28. Haghighatdoost F, Jabbari M, Hariri M. The effect of L-carnitine on
inflammatory mediators: a systematic review and meta-analysis of
randomized clinical trials. Eur J Clin Pharmacol. 2019;75(8):1037-46.
29. Harper P, Elwin C-E, Cederblad G. Pharmacokinetics of bolus
intravenous and oral doses of L-carnitine in healthy subjects. European
journal of clinical pharmacology. 1988;35(1):69-75.
30. Bain MA, Milne RW, Evans AM. Disposition and metabolite kinetics of
oral l‐carnitine in humans. The Journal of Clinical Pharmacology.
2006;46(10):1163-70.
31. El-Sheikh AA, Rifaai RA. Peroxisome proliferator activator receptor
(PPAR)-γ ligand, but not PPAR-α, ameliorates cyclophosphamide-induced
oxidative stress and inflammation in rat liver. PPAR research.
2014;2014.
32. Chen K, Li J, Wang J, Xia Y, Dai W, Wang F, et al. 15-Deoxy-γ12,
14-prostaglandin J2 reduces liver impairment in a model of ConA-induced
acute hepatic inflammation by activation of PPARγ and reduction in NF-κB
activity. PPAR research. 2014;2014.
33. Chung K-P, Chen G-Y, Chuang T-Y, Huang Y-T, Chang H-T, Chen Y-F, et
al. Increased plasma acetylcarnitine in sepsis is associated with
multiple organ dysfunction and mortality: a multicenter cohort study.
Critical care medicine. 2019;47(2):210-8.
34. Bonafé L, Berger MM, Que YA, Mechanick JI. Carnitine deficiency in
chronic critical illness. Current Opinion in Clinical Nutrition &
Metabolic Care. 2014;17(2):200-9.
35. Jones AE, Puskarich MA, Shapiro NI, Guirgis FW, Runyon M, Adams JY,
et al. Effect of Levocarnitine vs Placebo as an Adjunctive Treatment for
Septic Shock: The Rapid Administration of Carnitine in Sepsis (RACE)
Randomized Clinical Trial. JAMA Netw Open. 2018;1(8):e186076.
36. Puskarich MA, Kline JA, Krabill V, Claremont H, Jones AE.
Preliminary Safety and Efficacy of L‐carnitine Infusion for the
Treatment of Vasopressor‐Dependent Septic Shock: A Randomized Control
Trial. Journal of Parenteral and Enteral Nutrition. 2014;38(6):736-43.
37. Goetzman ES, Alcorn JF, Bharathi SS, Uppala R, McHugh KJ, Kosmider
B, et al. Long-chain acyl-CoA dehydrogenase deficiency as a cause of
pulmonary surfactant dysfunction. Journal of Biological Chemistry.
2014;289(15):10668-79.
38. Jennaro, T. S., M. A. Puskarich, et al. ”Using Lâ\euroCarnitine
as a Pharmacologic Probe of the Interpatient and Metabolic Variability
of Sepsis.” Pharmacotherapy: The Journal of Human Pharmacology and Drug
Therapy 40(9): 913-923.